Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Pulmonology

The Biology of LAM: Engines and Brakes

At a Glance

Lymphangioleiomyomatosis (LAM) is caused by mutations in the TSC1 or TSC2 genes, which normally act as brakes on cellular growth. Without these brakes, the mTOR pathway stays hyperactive, causing abnormal cells to multiply and travel to the lungs.

At its core, LAM is a disease of “unregulated growth.” To understand why it happens, it helps to think of your cells as having a powerful engine and a specialized set of brakes. (If you want a basic overview of the disease first, see What is LAM?).

The mTOR Engine and the TSC Brakes

Every cell in your body contains a pathway called mTOR (mechanistic Target of Rapamycin) [1]. Think of mTOR as a cellular engine that tells the cell when to grow, divide, and survive [2]. In a healthy cell, this engine is carefully controlled by two genes: TSC1 and TSC2 [3].

The TSC1/TSC2 complex acts like a “brake system.” When your body doesn’t need new cells, these genes keep the mTOR engine in check [1][4]. In LAM, one of these “brakes” is broken due to a genetic mutation [5]. Without the brake, the mTOR engine gets stuck in the “ON” position (hyperactivation), causing cells to grow and multiply when they shouldn’t [6][7]. These abnormal cells then travel to the lungs and other organs, leading to the symptoms of LAM [5].

Two Ways the Brakes Break

There are two distinct ways a person can develop LAM. While the effect on the lungs is similar, the genetic “how” and the impact on the rest of the body are different.

1. Sporadic LAM (S-LAM)

The most common form is “sporadic,” meaning it happens by chance.

  • The Cause: It is caused by somatic mutations [8]. This means the “brake” breaks in a single cell at some point during your life. It is not something you were born with, and you cannot pass it on to your children [8].
  • Who it Affects: This form almost exclusively affects women [9].
  • Systemic Reach: It is usually limited to the lungs, the lymphatic system, and the kidneys [9][10].

2. TSC-Associated LAM (TSC-LAM)

This form occurs in people who have a condition called Tuberous Sclerosis Complex (TSC).

  • The Cause: It is caused by germline mutations [8]. This means the “brake” was broken in the very first cell that formed you. It is present in every cell of your body and can be inherited from a parent or passed to a child [11].
  • Who it Affects: While LAM symptoms still mostly appear in women, men with TSC can also develop lung cysts [12][10].
  • Systemic Reach: Because the mutation is in every cell, it can cause growths in many organs [13].

Comparing the Subtypes

While having “TSC-LAM” means more parts of the body might be involved, research suggests that the lung disease itself is often milder in the TSC version compared to the sporadic version [13].

Feature Sporadic LAM (S-LAM) TSC-Associated LAM (TSC-LAM)
Inheritance Not inherited; happens by chance [8] Can be inherited; present from birth [11]
Genetic Test Mutation found only in LAM cells [8] Mutation found in all cells (blood test) [8]
Kidney Growths Common (Renal AMLs) [9] Very Common & often larger/multiple [13]
Brain/Skin Extremely rare [13] Common (tubers in brain, skin spots) [13]
Lung Severity Can be more progressive [13] Often more stable or slower to progress [13]

Why This Matters

Understanding that your disease is driven by a “stuck” mTOR engine is empowering because it explains why treatments like sirolimus work. Sirolimus acts as an “artificial brake,” manually slowing down the mTOR engine to help stabilize your lung function [5][7]. To read more about how this medication is used, visit Treating and Managing LAM. Knowing your subtype (S-LAM vs. TSC-LAM) also helps your doctors know exactly where else in the body they need to look to keep you healthy.

Common questions in this guide

What is the difference between sporadic LAM (S-LAM) and TSC-associated LAM?
Sporadic LAM is caused by a chance mutation that occurs during your lifetime and mainly affects the lungs, lymphatic system, and kidneys. TSC-associated LAM is a genetic condition present from birth that can affect multiple organs, including the brain and skin.
Can I pass LAM on to my children?
If you have sporadic LAM (S-LAM), you cannot pass the disease to your children because the mutation only happened in certain cells. However, if you have TSC-associated LAM, the genetic mutation is in all your cells and can be inherited by your children.
What are the TSC1 and TSC2 genes?
The TSC1 and TSC2 genes act as a natural brake system for your cells. They control a cellular pathway called mTOR to prevent unnecessary cell growth. In LAM, a mutation in one of these genes removes the brakes, leading to unregulated cell growth.
How does sirolimus work to treat LAM?
Sirolimus acts as an artificial brake on your cells. It manually slows down the hyperactive mTOR engine caused by TSC mutations, which helps reduce abnormal cell growth and stabilize your lung function.
Why do I need to be screened for other issues if I have TSC-LAM?
Because the genetic mutation in TSC-LAM is present in every cell of the body, it can cause non-cancerous growths in other organs. Your doctor may screen you for signs of Tuberous Sclerosis Complex, such as skin spots or neurological issues.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my LAM considered sporadic (S-LAM) or TSC-associated (TSC-LAM)?
  2. 2.Should I be screened for other signs of Tuberous Sclerosis Complex, such as skin lesions or neurological involvement?
  3. 3.Does my mutation (TSC1 vs. TSC2) have any impact on how we should approach my treatment?
  4. 4.If I have TSC-LAM, what are the chances of passing this genetic mutation to my children?
  5. 5.How does sirolimus specifically 'fix' the broken brake system in my cells?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Molecular logic of mTORC1 signalling as a metabolic rheostat.

    Valvezan AJ, Manning BD

    Nature metabolism 2019; (1(3)):321-333 doi:10.1038/s42255-019-0038-7.

    PMID: 32694720
  2. 2

    White Adipocyte Stem Cell Expansion Through Infant Formula Feeding: New Insights into Epigenetic Programming Explaining the Early Protein Hypothesis of Obesity.

    Melnik BC, Weiskirchen R, John SM, et al.

    International journal of molecular sciences 2025; (26(10)) doi:10.3390/ijms26104493.

    PMID: 40429638
  3. 3

    Structural insights into TSC complex assembly and GAP activity on Rheb.

    Yang H, Yu Z, Chen X, et al.

    Nature communications 2021; (12(1)):339 doi:10.1038/s41467-020-20522-4.

    PMID: 33436626
  4. 4

    Regulation of mTORC1 by PI3K signaling.

    Dibble CC, Cantley LC

    Trends in cell biology 2015; (25(9)):545-55.

    PMID: 26159692
  5. 5

    CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis.

    Evans JF, Obraztsova K, Lin SM, Krymskaya VP

    International journal of molecular sciences 2021; (22(5)) doi:10.3390/ijms22052233.

    PMID: 33668092
  6. 6

    Tuberous Sclerosis Complex Associated with Vascular Anomalies or Overgrowth.

    Jenkins D, McCuaig C, Drolet BA, et al.

    Pediatric dermatology 2016; (33(5)):536-42 doi:10.1111/pde.12946.

    PMID: 27470532
  7. 7

    The TSC Complex-mTORC1 Axis: From Lysosomes to Stress Granules and Back.

    Rehbein U, Prentzell MT, Cadena Sandoval M, et al.

    Frontiers in cell and developmental biology 2021; (9()):751892 doi:10.3389/fcell.2021.751892.

    PMID: 34778262
  8. 8

    Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing.

    Fujita A, Ando K, Kobayashi E, et al.

    Human genetics 2016; (135(1)):61-8 doi:10.1007/s00439-015-1611-0.

    PMID: 26563443
  9. 9

    Clinical features and outcomes of male patients with lymphangioleiomyomatosis: A review.

    Zhang H, Hu Z, Wang S, et al.

    Medicine 2022; (101(52)):e32492 doi:10.1097/MD.0000000000032492.

    PMID: 36596036
  10. 10

    Lymphangioleiomyomatosis.

    Xu KF, Xu W, Liu S, et al.

    Seminars in respiratory and critical care medicine 2020; (41(2)):256-268 doi:10.1055/s-0040-1702195.

    PMID: 32279296
  11. 11

    Ten-year follow-up of monozygotic twin sisters with TSC-LAM: A rare case report.

    Fan L, Elia D, Cassandro R, Harari SA

    Respiratory medicine case reports 2026; (62()):102436 doi:10.1016/j.rmcr.2026.102436.

    PMID: 42211577
  12. 12

    Tuberous sclerosis complex for the pulmonologist.

    Rebaine Y, Nasser M, Girerd B, et al.

    European respiratory review : an official journal of the European Respiratory Society 2021; (30(161)) doi:10.1183/16000617.0348-2020.

    PMID: 34348978
  13. 13

    Clinical, tomographic and functional comparison of sporadic and tuberous sclerosis complex-associated forms of lymphangioleiomyomatosis: a retrospective cohort study.

    Oliveira MR, Wanderley M, Freitas CSG, et al.

    ERJ open research 2024; (10(2)) doi:10.1183/23120541.00759-2023.

    PMID: 38444661

This page explains the biology and genetics of LAM for educational purposes only. Always consult your pulmonologist or genetic counselor regarding your specific diagnosis, genetic risks, and treatment plan.

Get notified when new evidence is published on Lymphangioleiomyomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.